Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0

Now that the board has woken up, perhaps we can discuss the latest PR as well. A couple of months ago Qiagen would have gone through the roof mentioning this research and today we saw a big drop. When we had the whole hype about the genome mapping, this was one of the examples I heard most frequently of how the mapping would be useful. I know the market overreacted back then, but surely everybody scrambling to get in must have known it was for the long term? Why then the drop now that Qiagen announces that they're working hard on the subject?


Genomics Collaborative and QIAGEN Genomics Announce Joint Research AgreementUnique Project to Combine QIAGEN Genomics' Single Nucleotide Polymorphism Genotyping With Genomics Collaborative's Disease Association Capabilities

Business Wire
SEATTLE & CAMBRIDGE, Mass., Jan 8, 2001 (BW HealthWire) -- QIAGEN Genomics,
Inc., a wholly-owned subsidiary of QIAGEN N.V. (Nasdaq: QGENF; Frankfurt/Neuer
Markt:QIA; Easdaq: QGEN) and Genomics Collaborative Inc. (GCI) today announced
they have entered into a collaboration to analyze genetic profiles of
geographically distinct patient populations with known poor drug metabolism
against an equal subset of control patients who have no reported adverse events
to the leading metabolism enzymes. Effective July 2000, the companies formed an
alliance to offer an integrated solution combining GCI's sample repository and
database services with QIAGEN Genomics' high throughput single nucleotide
polymorphism (SNP) genotyping services. The companies expect that the project
will be completed in early spring 2001, and intend to submit the results of
their pharmacogenomic findings for publication. The agreement announced today
will further leverage each company's unique genomics services capabilities.

As the mapping of the human genome nears completion, a growing effort is
focusing on the elucidation of SNPs and the longer-term determination of their
clinical relevance. These broad-based efforts focusing on SNPs require sample
and patient data resources to access specific patient populations with carefully
defined clinical profiles as well as proven, accurate and reproducible high
throughput SNP measurement methods to score, or measure, the SNPs in association
with patient DNA.

For the companies' new collaboration, believed to be the most extensive study of
its kind yet to be conducted, sample test and control populations are being
selected from GCI's Global Repository(TM) and will be chosen on the basis of
known drug metabolism and adverse drug reaction. "We believe that drug companies
will save costs and reduce the time associated with developing new drugs by
having access to patient profiles that can predict individual patient response
with regards to drug absorption, distribution, metabolism and excretion
outcomes," said William Hirschman, GCI's Vice President, Business Development.

"We are excited to further our alliance with QIAGEN Genomics," said Michael
Pellini, MD GCI's Chief Executive Officer. "We believe that this unique
combination of services will be responsive to the pharmacogenomic and discovery
needs of the pharmaceutical and biotech industry."

"Searching for genotypic and phenotypic associations requires access to well
phenotyped, properly consented DNA and tissue samples and medical histories from
large numbers of patients," said Karen Hedine, QIAGEN Genomics' General Manager.
"We feel that this study is a significant step forward in the next generation of
gene-based drug discovery and diagnostic development."

QIAGEN Genomics believes it is the world's first commercial, high throughput,
SNP genotyping services provider. The company to date has measured well over a
million genotypes on behalf of clients in its dedicated, first-of-its-kind, good
laboratory practices and quality-oriented services facility. QIAGEN Genomics'
proprietary Masscode(TM) tagging approach to SNP genotyping requires very small
amounts of genomic DNA to perform at highest standards. This is a significant
benefit considering the often very limited amounts of patient samples available.
In addition, analyses applying the Masscode tags are highly quantitative,
accurate and cost effective. QIAGEN Genomics uses its Masscode tagging chemistry
in combination with low cost yet highly accurate and quantitative single
quadruple mass spectrometry - enabling the company to perform over 40 million
genotypes annually. QIAGEN Genomics, formerly known as Rapigene, Inc., is
located near Seattle, Washington. The company also offers nucleic acid
extraction, DNA sequencing and other genomics-related services in addition to
Masscode technology access programs. Additional information concerning the
Company can be found at www.qiagengenomics.com.

Genomics Collaborative, Inc. (GCI) is a genomics company focused on discovering
previously unknown relationships between human genetic variation and the nature
of important diseases. The company's scientific strategy is to utilize its LARGE
SCALE GLOBAL GENOMICS(TM) Platform to exploit the power of
appropriately-designed genetic associations studies. Such studies are designed
to detect subtle associations between genetic variation and disease incidence,
severity or treatment, and are dependent upon the availability of large numbers
of well-characterized patients and the tools with which to analyze their genetic
information. GCI intends to conduct these studies and apply any resulting
discoveries to the development of high value pharmaceutical products pursuant to
collaborations with pharmaceutical, biotechnology and genomics companies, and on
its own.

etc.
http://quote.fool.com/news/symbolnews.asp?symbols=QGENF&currticker=QGENF&format=fraction&lpp=10&dtfrom=10%2F9%2F2000+4%3A26%3A46+AM&dtto=1%2F9%2F2001+4%3A26%3A46+AM&sourcetype=1&exch=NYSE%2CNASDAQ%2CAMEX%2CMF%2CU%2CUS%2CUSMF&cdnsortby=Date&sid=503890&pos=0&action=gs

eveline



Print the post  

Announcements

When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement